Goldman Sachs
CLDI icon

Goldman Sachs’s Calidi Biotherapeutics CLDI Stock Holding History

Goldman Sachs’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-69
Closed -$3.04K – 6366
2025
Q2 		$3.04K Buy
+69
New +$5.36K ﹤0.01% 6034
2025
Q1 		– Sell
-91
Closed -$20.1K – 6104
2024
Q4 		$20.1K Buy
+91
New +$27.3K ﹤0.01% 5895
2022
Q3 		– Sell
-66
Closed -$1.26M – 6292
2022
Q2 		$1.26M Hold
66
– – ﹤0.01% 4437
2022
Q1 		$1.26M Buy
66
+19
+40% +$359K ﹤0.01% 4646
2021
Q4 		$883K Buy
+47
New +$886K ﹤0.01% 4953

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Goldman Sachs's CLDI Position: Q3 2025 in Review

Goldman Sachs sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 69 shares — an estimated $3.04K sold.

Goldman Sachs first reported a position in CLDI in Q4 2021 and held it in 5 quarters. The position peaked at $1.26M in Q1 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • Goldman Sachs reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 69 Calidi Biotherapeutics shares in Q3 2025, an estimated $3.04K.
  • Goldman Sachs first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Goldman Sachs's Calidi Biotherapeutics position peaked at $1.26M in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.